1. Home
  2. SPRY vs GSBD Comparison

SPRY vs GSBD Comparison

Compare SPRY & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$9.11

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

GSBD

Goldman Sachs BDC Inc.

HOLD

Current Price

$9.37

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRY
GSBD
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
SPRY
GSBD
Price
$9.11
$9.37
Analyst Decision
Strong Buy
Sell
Analyst Count
2
2
Target Price
$35.00
$9.00
AVG Volume (30 Days)
889.4K
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
13.76%
EPS Growth
114.04
87.27
EPS
N/A
1.03
Revenue
$89,149,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$119.97
N/A
P/E Ratio
N/A
$9.05
Revenue Growth
297063.34
N/A
52 Week Low
$6.66
$8.81
52 Week High
$18.63
$12.43

Technical Indicators

Market Signals
Indicator
SPRY
GSBD
Relative Strength Index (RSI) 42.09 53.25
Support Level $8.61 $8.99
Resistance Level $10.44 $9.55
Average True Range (ATR) 0.44 0.23
MACD 0.03 0.02
Stochastic Oscillator 40.31 77.21

Price Performance

Historical Comparison
SPRY
GSBD

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: